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Care Unit (ICU) Inpatients
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ABSTRACT: Stress ulcer prophylaxis (SUP) is largely prescribed to ICU and non-ICU patients. SUP, an acid-sup-
pressive drug, is overused in hospital settings mainly due to inadequate prescriptions in low-risk patients. In this 
context, the appropriate administration of SUP needs to be analyzed, and the potentially saved money from re-
ducing excessive use can thereby be quantified. This study was intended to calculate potential cost savings in in-
appropriate SUP therapy in non-ICU inpatients. With a non-experimental retrospective design, it analyzed medi-
cal records and details obtained from the financial department of “X” hospital in Purwokerto, Indonesia. The data 
were collected from 80 non-ICU inpatients in May 2015, which were selected by purposive sampling. We calcula-
ted potential cost savings by referring to the American Society of Health-System Pharmacists (ASHP) guidelines 
that had been modified by Zeitoun (2011) for stress ulcer prophylaxis in non-ICU inpatients. The results showed 
that inappropriate indications and doses were found in 32.5% and 18% of selected patients, respectively. Before 
the cost-saving calculation, patients had to spend USD 2,411. However, after the analysis eliminated unnecessary 
SUP use, this number was proven to be potentially decreased by USD 512 to only USD 1,899. Based on the Wil-
coxon Sign Rank Test result (p = 0.000 (≤ 0.05)), there was a significant difference between the total cost before 
and after the application of modified ASHP guidelines for appropriateness. After a thorough assessment, we con-
cluded that the treatment cost could be reduced by identifying and excluding inappropriateness in SUP therapy.
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1. Introduction
The cost of health services, especially pharma-
ceutical spending, increases every year. It appears to be inevitable as the population grows and 
patterns of diseases and treatments constantly 
change. The large size of the patient population 
is likely to increase drug use, including new drugs traded at a high price, and affect courses of medi-
cation [1]. Drug use can be rational if patients 
receive therapy fitting to their clinical needs and 
appropriate doses at the lowest possible cost. 
Also, therapy must respect the choices that pa-
tients have made. A component of the principles 
of rational drug use is considering the drug cost. 
Most importantly, health care providers are obli-gated to be able to choose cost-effective drugs for 
patients.
More than 50% of drugs are reportedly admi-nistered with inappropriate indications and do-ses, indicating ubiquitous cases of irrational drug 
use. The most common types of irrational drug 
use are polypharmacy and non-compliance with 
the guidelines. Moreover, 14.7% of 102 geriatric 
patients exhibit side effects of drug use that lead 
to hospitalization. There have been several stud-
ies highlighting many stress ulcer prophylaxis 
(SUP) prescribed, especially in Indonesia. Nine-
ty-three percent of ICU patients diagnosed with 
stroke receive SUP, especially ranitidine [2]. 
Stress ulcers are single or multiple gastroduo-denal mucosal defects that cause a broad range of 
clinical manifestations from superficial mucosal erosions or mild-severe ulceration to life-threa-
tening bleeding. The pathophysiology of stress ulcers is related to a reduction in mucosal blood 
flow or a breakdown in other normal mucosal defense mechanisms in conjunction with the in-jurious effects of acid and pepsin on the gastro-
duodenal mucosa. Since acid does appear to be involved in the pathogenesis of these lesions, acid-suppressive regimens have the potential to 
prevent stress ulcers [3]. Stress ulcer prophylaxis 
is commonly used to decrease gastrointestinal 
bleeding in critically ill patients. However, SUP is 
commonly used in non-critically ill patients des-
pite little evidence to support it [4]. 
Stress ulcers are managed by acid-suppressive 
drugs, such as Histamine-2 blockers (H2 blockers) 
and Proton Pump Inhibitor (PPI). The most com-
monly used H2 blockers are cimetidine and ranit-
idine [5]. PPI is more potent, such as omeprazole, 
lansoprazole, and pantoprazole. Se veral consen-
sus guidelines for SUP have been published. The most recent guidelines available were published 
by The American Society of Health-System Phar-
macists (ASHP) in 1999. These guidelines provide evidence-based recommendations for non-criti-
cally ill medical and surgical patients, critically ill 
patients, and ICU pediatric populations. Zeitoun 
(2011) has also modified these for non-critically 
ill patients [3]. 
Stress ulcer prophylaxis is largely prescribed 
in ICU and non-ICU patients. Scagliarini et al. 
(2005) have found that SUP is frequently over-used in hospital settings because of inadequate 
prescriptions in low-risk patients. Inappropriate 
use of SUP will expose patients to potential ad-
verse effects, such as Clostridium difficile-associ-
ated diarrhea, community-acquired pneumonia, 
malabsorption, osteoporosis, and hip fracture. 
Previous studies have shown that 56% to 75% of general medicine patients begin inappropri-
ate use of SUP in the hospital [6]. A retrospective 
chart review of medical and surgical ICU patients 
shows that 80% of patients transferred from 
the ICU continued to receive SUP (60% is inap-
propriate SUP), and 24.4% of those patients are 
discharged from the hospital with SUP and no ap-
propriate indication [7].
SUP may lead to adverse drug interactions 
(e.g., clopidogrel) and increase the risk of re-hos-
pitalization and additional health care costs [6]. 
The ICU-based study performed in a tertiary-care teaching hospital in Vancouver, British Columbia, Canada has concluded that after the introduc-
tion of a guideline for SUP administration, ap-
propriateness of therapy increases from 75.8% 
to 91.1%, and medication costs decrease from 
$2.50/day to $1.30/day without any statistically 
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significant difference in clinical outcomes. As for 
this study, it focuses on analyzing the appropri-
ate use of acid-suppressive drugs, namely SUP, and calculate the potential cost savings from its 
inappropriate use. It is very useful to know the potential cost saving from inappropriate or un-
necessary stress ulcer prophylaxis (SUP) therapy 
in non-ICU inpatients.
 
2. Methods
2.1. Design and setting
This non-experimental study was performed on medical records and details acquired from the 
financial department of "X" hospital in Purwoker-
to, Indonesia. Using a retrospective design and hospital perspective, we collected data from non-
ICU inpatients in May 2015. From a population of 
316 patients during this month, a minimum of 80 
patients was selected by purposive sampling ac-
cording to the predefined inclusion and exclusion 
criteria. This sample size was determined using 
the Slovin’s formula with a confidence level of 90.Patients were included in data collection if 
they used SUP, such as H2 blockers, proton pump 
inhibitor (PPI), sucralfate, and antacids. Mean-
while, they were excluded from data collection 
if they had gastric disorders (i.e., peptic ulcer di-
sease, nephrolithiasis phosphate, dyspepsia, gas-
troesophageal reflux disease (GERD), gastritis, 
duodenal ulcers, mucositis or stomatitis). 
We referred to ASHP guidelines for safe use of 
SUP (1999) that had been modified by Zeitoun 
(2011) for non-ICU inpatients [3], and then we calculated potential cost savings from inappro-
priate drug use. ASHP guidelines exhaustively include both independent and non-independent 
risk factors (Table 1). Indications are categorized as appropriate if patients have one of the indepen-
dent risk factors: (1) Patients with coagulopathy 
Table 1. Risk factors associated with stress ulcers
Types Risk factors Independent 1. Coagulopathy (including medication-induced coagu-
lopathy): platelet count < 50,000/mm3, INR > 1.5, or 
PTT > 2× control value
2. Respiratory failure: mechanical ventilation ≥ 48 hours
Others 1. Spinal cord injuries
2. Multiple trauma: trauma sustained to more than one 
body regions
3.  Hepatic failure: total bilirubin level > 5 mg/dL, AST > 
150 U/L (3× ULN), or ALT > 150 U/L (3× ULN)
4. Thermal injuries > 35% of body surface area
5. Partial hepatectomy
6. Head injury with Glasgow coma score of ≤ 10 or ina-
bility to obey simple commands
7. Hepatic or renal transplantation
8. History of gastric ulceration or bleeding during a year before admission
9. Sepsis/septic shock: vasopressor support and/or posi-tive microbiologic cultures/suspected infection
10. Intensive care unit stay for > 1 week
11. Occult or overt bleeding for > 6 days
INR: International Normalized Ratio
Adapted from: ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J Health-Syst Pharm 1999; 56:347–
79.
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(platelet count < 50,000 per mm3, International 
Normalized Ratio (INR) > 1.5 or PTT > 2x control 
value or drugs that affect coagulation, (2) using a 
ventilator for more than 48 hours, and (3) history of gastrointestinal bleeding or ulceration before entering the hospital, and if patients have at least 
two non-independent risk factors: (1) sepsis, (2) 
in the ICU for more than one week, (3) bleeding 
for 6 days or more, (4) taking high-dose cortico-
steroids (> 250 mg/day) [8].
2.2.  Data analysis
From the datasheet, we classified patients 
into several groups based on (1) demographic 
characteristics, such as gender, (2) SUP regimen 
that included use, dose, and duration, and (3) 
appropriateness according to ASHP/Zeitoun 
guidelines. The data were classified into either appropriate or inappropriate indications of stress ulcer, and then for inappropriate indications, 
we calculated the potential of cost-saving. Data 
on pharmaceutical spending, especially before and after the calculation of cost-saving, were 
analyzed in SPSS 20 program. The analysis also 
included the Kolmogorov Smirnov normality 
test and the Wilcoxon Sign Rank test to identify 
any differences between before and after the calculation of potential cost saving
3. Results and discussion 
Based on gender, 56.25% of the selected 80 
patients were males, and 43.75% of them were 
females (Table 2). This gender distribution is 
similar to Zeitoun et al. (2011), in which the share of male patients is larger than their female 
counterparts [3]. Kerama et al. (2014) also show 
that in a hospital ICU in Kenya, 57.5% of SUP 
users were male [7]. Furthermore, according to 
Chu et al. (2010), male patients have a higher risk 
of gastrointestinal bleeding (57.5%) than female 
patients (42.5%). 
The majority of the sampled patients (91%) 
underwent monotherapy, whereas only a few 
of them (9%) took combination therapy. Of the 
91% of patients with monotherapy, 69% of them 
received ranitidine, and the remaining 17% took 
omeprazole as stress ulcer prophylaxis. As for 
the combination therapy, more than half of the 
patients in this category (56%) took ranitidine 
IV combined with omeprazole PO. The non-ICU 
patients in "X" hospital in Purwokerto mostly 
used Histamine-2 blockers (H2RA) as SUP. H2RA 
inhibits histamine-stimulated acid secretion by 
reversible, competitive inhibition of H2 receptors 
on parietal cells. Among the available H2RA, cimetidine is the least potent, ranitidine is in the 
middle, and famotidine is the most potent [7]. In a 
meta-analysis by Cook et al.  various prophylactic 
therapies, including antacids, sucralfate, and H2-
RAs, have been found to reduce the incidence of 
clinically significant bleeding compared with no 
prophylaxis. However, antacids are no longer considered a viable therapeutic option because 
of the labor-intensive dosing frequency and 
potential side effects. According to the ASHP 
guidelines, SUP is not recommended for general 
medical and surgical patients in non-ICU settings 
with fewer than two risk factors for clinically 
significant bleeding or patients with two or more 
risk factors. A retrospective case-control study 
conducted by Qadeer et al. at an American tertiary 
care center (n =17707 patients) demonstrates that hospital-acquired bleeding is uncommon 
in non-critically ill patients; therefore, routine 
prophylaxis is unnecessary in most hospitalized 
patients [9]. Various agents that protect the gastric mucosa from acid have been used for 
SUP. Antacids such as aluminum and magnesium 
hydroxide were historically used because of their 
ability to buffer stomach acid. Sucralfate does 
not neutralize acid but forms a protective barrier 
over the gastric mucosa. Histamine-2 receptor 
antagonists (H2RAs) and proton pump inhibitors 
(PPIs) both inhibit gastric acid secretion. The 
non-ICU of "X" hospital in Purwokerto mostly 
used Histamine-2 blockers (H2RA). Appropriate indication of stress ulcers in non-
ICU settings according to ASHP guidelines must 
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have at least one of the independent risk factors 
or two/more non-independent risk factors. 
Zink et al. reviewed 814 general adult medicine 
admissions in a community hospital setting, of 
which 324 were given SUP (40% of total). They 
noted that 40% of patients receiving SUP were 
actually given acid-suppressive drugs for an appropriate medical indication (therefore not 
SUP), while 60% were not [10]. Our study showed 
that of 80 patients who received SUP, 67.50% had inappropriate stress ulcer indications and 
32.50% had appropriate indications. In 2010, 
Reid and colleagues conducted a retrospective 
review of the use of PPIs in 9875 patients in a 
university-affiliated public safety-net hospital 
and 6,520,100 patients in the University Health 
System Consortium. Of the nearly 1 million 
patients who received PPIs between 2008 and 
2009, 73% did not have a valid indication for 
acid-suppressive therapy. SUP was cited as the 
reason for inappropriate prescribing in 56% of 
cases. Duration of SUP use in our study varied 
from 1 to 16 days, and the largest dose of SUP use 
was for 5 days. Long-term use of acid-suppressive medications was associated with an increase in 
unnecessary expenses, and, most importantly, 
with an elevated risk of pneumonia, hip fracture, 
and Clostridium difficile colitis.
After the data were classified into either appropriate or inappropriate indications, then we calculated the potential cost saving from 
inappropriate indications. This cost-saving 
refers to the cost reduction of SUP use and drug 
administration kits (i.e., syringe and alcohol swab 
use) in patients with inappropriate indications. 
Data on pharmaceutical costs, especially before 
and after the application of ASHP guidelines, 
were analyzed in SPSS 20 program. The 
analysis also included the Kolmogorov Smirnov 
Normality test and the Wilcoxon Sign Rank Test 
to identify any differences between before and after the detection of inappropriateness based 
on ASHP guidelines. The results showed p = 
0.000 (≤ 0.05), which indicates that a significant difference between the total cost before and 
after the application of ASHP guidelines for the 
identification of inappropriateness. 
The overuse of SUP can have a substantial 
Patient characteristics n (%)
Gender    Male 
   Female
45 (56.25)
35 (43.75)
Therapy 
   Monotherapy
   Combination therapy
73 (91)
7 (9)Acid-suppressive drugs mono-
therapy 
   Ranitidine
   Lansoprazole
   Omeprazole   Antacid
   Sucralfate
56 (69)
8 (10)
14 (17)
1 (1)
2 (3)
Combination therapy 
   Ranitidine iv + pantoprazole iv
   Ranitidine iv + omeprazole iv 
   Ranitidine iv + omeprazole po 
1 (11)
3 (33)
5 (56)
Table 2. General characteristics of the samples (n 
=80)
iv: intravenous, po: per oral
SUP variables (%)
Risk factors (appropriate indications)
   Coagulopathy  
   Coagulopathy + sepsis
   Coagulopathy + corticosteroids high   dose
88
8
4Dose     Appropriate   Inappropriate 189
Table 3. Stress ulcer prophylaxis use with appro-priate indications
Before ASHP After ASHP Potential Cost 
Saving
USD 2,411 USD 1,899 USD 512
Table 4. The potential cost savings from inappro-priate indications
USD 1 = IDR 13,164 (based on Bank Indonesia, ex-
change rate on January 31, 2018)
economic impact on both patients and the 
health care system. The study by Heidelbaugh 
and colleagues, which included 1769 general 
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medicine patients at a major university hospital, 
found that the inappropriate use of SUP 
increased annual inpatient costs by USD 44,096 
and outpatient costs by USD 67,695, for a total 
of USD 111,791 [11]. In a large managed care 
organization, in which 68% of 29,348 patients 
were prescribed a PPI inappropriately at hospital 
discharge, inappropriate continuation for just 30 
days after discharge was associated with a cost 
of more than $3 million over 4 years. Neither of 
these studies took into account the costs incurred 
from complications of SUP therapy [12].  Another 
ICU-based study performed in a tertiary-care teaching hospital in Vancouver, British Columbia, Canada concluded that after the introduction of a 
guideline for SUP administration, appropriateness 
of therapy increased from 75.8% to 91.1%, and 
medication costs decreased from USD 2.50/day to 
USD 1.30/day without any statistically significant 
difference in clinical outcomes. In our study, the 
cost-saving refers to the cost reduction of SUP 
use and drug administration kits (i.e., syringe and alcohol swab use) in patients with inappropriate 
indications. The total cost potentially saved due 
to inappropriate indications was IDR 6,739,498 
or equal to USD 512. The data were examined 
using the Wilcoxon Sign Rank Test, and the results 
showed p = 0.000 (≤ 0.05), indicating a significant difference between the total cost before and after 
the cost-saving calculation.
4. ConclusionThe percentages of inappropriate indications 
and doses are 32.5% and 18%, respectively. After 
the introduction of ASHP guidelines for appropri-
ateness, the total cost decreases from USD 2,411 
to USD 1,899. In other terms, the potential cost-
saving from inappropriate indications is USD 512. 
Based on the Wilcoxon Sign Rank Test results (p 
= 0.000 (≤0.005)), there is a significant difference between the total cost before and after the intro-
duction of ASHP guidelines for appropriateness.
Acknowledgment
The authors would like to thank LPPM 
University of Jenderal Soedirman for funding our 
study and Oktavilia Perdini for her assistance 
during data collection.
Reference
1. Trisna Y.   Pharmacoeconomy. Pharmacy 
Development 2011, Ikatan Apoteker Indonesia: 
Jakarta.
2. Farizal. Drug Related Problems (DRPs) in Stroke 
ICU Patients Stroke Nasional Hospital Bukittinggi 
(dissertation). Andalas University; 2011.
3. Zeitoun A, Zeineddine M, Dimassi H. Stress 
Ulcer Prophylaxis  Guidelines: Are They 
Being Implemented in Lebanese Health Care 
Centers?. World J Gastrointest Pharmacol Ther. 
2011;2(4):27-35.
4. Jain G, Jabeen SA, Vallurupalli S. Efforts to reduce 
stress ulcer prophylaxis use in non-critically 
ill hospitalized patients by internal medicine 
residents: a single-institution experience. J Clin 
Outcomes Manag. 2013;20(1):13-9.
5. Aziz N. Role of Antagonist H2 Receptors in Stress 
Ulcer Treatment. Sari Pediatri. 2002;3(4):222-7.
6. Scagliarini R, Magnani E, Praticò A, Bocchini 
R, Sambo P, Pazzi P. Inadequate Use of Acid-
Suppressive Therapy in Hospitalized Patients 
and Its Implications for General Practice. Dig Dis 
Sci. 2005;50(12):2307-11.
7. Mohebbi L, Hesch K. Stress Ulcer Prophylaxis 
in Intensive Care Unit. Pharmacology Notes. 
2009;22(4):373-6.
8. American Society of Health-System Pharmacists. 
ASHP Therapeutic Guidelines on Stress 
Ulcer prophylaxis. Am J Health Syst Pharm. 
1999;56:347-9.
9. Qadeer MA, Richter JE, Brotman DJ. Hospital-
Acquired Gastrointestinal Bleeding Outside 
the Critical Care Unit: Risk Factors, Role of Acid 
Suppression, and Endoscopy Findings. J Hosp 
Med. 2006;1(1):13-20.
Cost Saving of Stress Ulcer Prophylaxis Used in Non-Intensive Care Unit (ICU) Inpatients
Media Pharmaceutica Indonesiana ¿ Vol. 3 No. 1 ¿ June 2020 43
Hening Pratiwi, Laksmi Maharani, dan Ika Mustikaningtias
10. Zink DA, Pohlman M, Barnes M, et al. Long-term 
Use of Acid Suppression Started Inappropriately 
During Hospitalization. Aliment Pharmacol Ther. 
2005;21(10):1203-9.
11. Heidelbaugh JJ, Inadomi JM. Magnitude and 
Economic Impact of Inappropriate Use of Stress 
Ulcer Prophylaxis in Non-ICU Hospitalized 
Patients. Am J Gastroenterol. 2006;101(10):2200-
5
12. Anderson ME. Stress Ulcer Prophylaxis 
in Hospitalized Patients. Hosp Med Clin. 
2013;1(2):e32-44.
